Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aerovate Therapeutics Inc
(NQ:
AVTE
)
2.340
-0.030 (-1.27%)
Streaming Delayed Price
Updated: 9:44 AM EDT, Oct 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aerovate Therapeutics Inc
< Previous
1
2
3
4
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 01, 2024
Via
Benzinga
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
August 12, 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Aerovate Therapeutics to Explore Strategic Alternatives
July 08, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
The 3 Hottest Stock Downgrades From Last Week
June 27, 2024
Explore the experts' latest surprising stock downgrades amid significant market shifts and analyst adjustments.
Via
InvestorPlace
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
June 17, 2024
Via
Benzinga
Recap: Aerovate Therapeutics Q4 Earnings
March 25, 2024
Via
Benzinga
Recap: Aerovate Therapeutics Q3 Earnings
November 13, 2023
Via
Benzinga
Recap: Aerovate Therapeutics Q1 Earnings
May 15, 2023
Via
Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 17, 2024
Via
Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
June 17, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
June 17, 2024
The company was working on a treatment for pulmonary arterial hypertension, a form of high blood pressure in the lungs.
Via
Investor's Business Daily
Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
June 17, 2024
Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary...
Via
Benzinga
US Stocks Mixed; Dow Tumbles Over 100 Points
June 17, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
June 17, 2024
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
May 21, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
May 13, 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 13, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
April 05, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply during Friday’s session as the company reported FY23...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
March 27, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023
March 25, 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
March 25, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
March 06, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
November 20, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
November 13, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
August 14, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
July 11, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 01, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
May 22, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 15, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.